Vir Biotechnology (VIR) Reports 80.98% Year-to-Date Stock Growth
Vir Biotechnology (NASDAQ:VIR) has seen an 80.98% year-to-date increase in its stock price, driven by a global collaboration and licensing agreement with Astellas. The deal includes a $240 million upfront payment and potential future milestones totaling up to $1.37 billion.
Topics: biotech collaboration financial performance licensing agreement pharmaceuticals